Bulimia Nervosa Market Projected To Grow Radiantly; Asserts MRFR Unleashing Industry Forecast

Global Bulimia Nervosa Market   - Overview

Bulimia nervosa is an eating disorder associated with eating a large amount of food in short time. People suffering from bulimia nervosa is increasing continuously around the globe. As eating disorders are triggered by negative energy balance accompanied by weight loss. Factors like stress, fat-shaming, nutrition education, pressure to be thin and many more are responsible causing this disorder. Diseases like diabetes and many other cardiovascular diseases are also responsible for increasing the market on bulimia nervosa. High cost of treatment is the major restraining factor for the growth of the market. Global Bulimia Nervosa Market is anticipated to reach USD 735.8 Million by 2030 at 6% CAGR during the forecast period 2022-2030.

According to findings from the WHO in 2014, approximately 422 million people suffered from diabetes. Due to the increasing diabetic population across the globe there is a significant increase in the number of people suffering from cardiovascular diseases. Additionally, increasing geriatric population and increasing healthcare expenditure have fuelled the growth of the market.

According to the World Health Organization (WHO), in 2015, over 17.7 million people died from cardiovascular diseases, representing 31% of all global deaths. According to the Centers for Disease Control and Prevention (2015), over 630,000 Americans died from heart disease each year, which accounted for 1 in every 4 deaths. According to findings from the WHO, in 2015, 82% of the total deaths were occurred in low- and middle-income countries. Beside this, globally 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese.

 Global Bulimia Nervosa Market   - Competitive Analysis

Siemens Healthcare GmbH (Germany), Philips Healthcare (U.S), Abbott (U.S), Johnson & Johnson Services, Inc.(U.S), Stryker (U.S), General Electric Company (U.K), Covidien ltd (Ireland), AstraZeneca (U.K) Penumbra, Inc. (U.S) are some of the prominent players at the forefront of competition in the Global Bulimia Nervosa Market and are profiled in MRFR Analysis. 

Due to increasing prevalence of bulimia nervosa across the globe many of the companies are in the race to introduce better treatment for bulimia nervosa. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.

AstraZeneca is a multinational pharmaceutical and biopharmaceutical company headquartered in UK. Recently AstraZeneca has completed its collaboration with National Institute of Mental Health. This collaboration will help to discover the new and better drug treatment for distressing condition. AstraZeneca has also collaborated with Vanderbilt Center for the Neuroscience Drug Discovery which aims to discover new drug for the treatment of neuropsychiatric disorders.

Global Bulimia Nervosa Market   -

Regional Analysis

On regional basis, North America has the leading bulimia nervosa market due to increasing prevalence of this disorder in North America. 6.2 million People are suffering with this bulimia nervosa in North America majority of them are young adults. Beside this unmet need of medication and technological advances is the other factor for growth of this market in North America.

According to World Population Ageing Report, in 2017, there are an estimated 962 million people aged 60 or over globally, which is 13% of the total global population. According to the population reference bureau, the number of Americans ageing 65 and older is projected to more than double from 46 million in 2015 to over 98 million by 2060. According to the StastsCan, 2015, over 5.7 million Canadians have aged 65 and older, which was 16.1 % of Canadian population. According to Statistics Canada projections, this trend will only increase. By 2031, one in four Canadians will be over 65 age. According to the WHO, 2015, Asia's elderly population is projected to reach nearly 923 million by 2050. Growing geriatric is fuelling the number of patients suffering from cardiovascular diseases owing to the high susceptibility of this population pool to developing cardiovascular diseases. Increasing geriatric population will increase the market for cardiovascular devices since they are more vulnerable towards cardiovascular diseases such as hypertension, stroke, and other diseases. Moreover, increasing healthcare expenditure has provided fuel for the growth of the market.

North America is followed by Europe in bulimia nervosa market. Increasing number of diabetic population, patents suffering from other cardiovascular diseases, technological advances and well developed healthcare sector has led to grow this market in Europe. Asia Pacific is the fastest growing market due to a huge population base and increasing prevalence of diabetes and other bulimia nervosa causing disease. The Middle East & Africa has the least market for bulimia nervosa.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Bulimia Nervosa Market Research Report